WallStSmart

Marvell Technology Group Ltd (MRVL)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 590% more annual revenue ($56.58B vs $8.19B). MRVL leads profitability with a 32.6% profit margin vs 23.9%. MRVL appears more attractively valued with a PEG of 1.84. MRVL earns a higher WallStSmart Score of 66/100 (B-).

MRVL

Strong Buy

66

out of 100

Grade: B-

Growth: 8.7Profit: 8.0Value: 3.7Quality: 7.0
Piotroski: 5/9Altman Z: 1.80

NVS

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 4.0Quality: 5.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for MRVL.

NVSSignificantly Overvalued (-52.5%)

Margin of Safety

-52.5%

Fair Value

$109.60

Current Price

$147.85

$38.25 premium

UndervaluedFair: $109.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRVL4 strengths · Avg: 9.3/10
Profit MarginProfitability
32.6%10/10

Keeps 33 of every $100 in revenue as profit

EPS GrowthGrowth
106.3%10/10

Earnings expanding 106.3% YoY

Market CapQuality
$144.42B9/10

Large-cap with strong market position

Revenue GrowthGrowth
22.1%8/10

Revenue surging 22.1% year-over-year

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$282.11B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

MRVL4 concerns · Avg: 3.5/10
PEG RatioValuation
1.844/10

Expensive relative to growth rate

Price/BookValuation
9.8x4/10

Trading at 9.8x book value

Altman Z-ScoreHealth
1.804/10

Grey zone — moderate risk

P/E RatioValuation
53.8x2/10

Premium valuation, high expectations priced in

NVS4 concerns · Avg: 3.0/10
PEG RatioValuation
2.484/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-9.3%2/10

Earnings declined 9.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRVL

The strongest argument for MRVL centers on Profit Margin, EPS Growth, Market Cap. Profitability is solid with margins at 32.6% and operating margin at 18.7%. Revenue growth of 22.1% demonstrates continued momentum.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bear Case : MRVL

The primary concerns for MRVL are PEG Ratio, Price/Book, Altman Z-Score. A P/E of 53.8x leaves little room for execution misses.

Bear Case : NVS

The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.

Key Dynamics to Monitor

MRVL profiles as a growth stock while NVS is a declining play — different risk/reward profiles.

MRVL carries more volatility with a beta of 1.82 — expect wider price swings.

MRVL is growing revenue faster at 22.1% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRVL scores higher overall (66/100 vs 51/100), backed by strong 32.6% margins and 22.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Marvell Technology Group Ltd

TECHNOLOGY · SEMICONDUCTORS · USA

Marvell Technology, Inc. designs, develops, and sells analog, mixed-signal, digital signal processing, and integrated and independent integrated circuits. The company is headquartered in Wilmington, Delaware.

Visit Website →

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?